| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CPA1 |
| Uniprot No | P15085 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 17-419aa |
| 氨基酸序列 | KEDFVGHQVLRISVADEAQVQKVKELEDLEHLQLDFWRGPAHPGSPIDVR VPFPSIQAVKIFLESHGISYETMIEDVQSLLDEEQEQMFAFRSRARSTDT FNYATYHTLEEIYDFLDLLVAENPHLVSKIQIGNTYEGRPIYVLKFSTGG SKRPAIWIDTGIHSREWVTQASGVWFAKKITQDYGQDAAFTAILDTLDIF LEIVTNPDGFAFTHSTNRMWRKTRSHTAGSLCIGVDPNRNWDAGFGLSGA SSNPCSETYRGKFANSEVEVKSIVDFVKDHGNIKAFISIHSYSQLLMYPY GYKTEPVPDQDELDQLSKAAVTALASLYGTKFNYGSIIKAIYQASGSTID WTYSQGIKYSFTFELRDTGRYGFLLPASQIIPTAKETWLALLTIMEHTLN HPYVDHHHHHH |
| 预测分子量 | 47 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是我根据学术文献格式模拟的3篇关于CPA1重组蛋白的参考文献示例(注：以下为虚构示例，实际文献需通过学术数据库获取)：
1. **文献名称**: *Structural characterization of recombinant human CPA1 expressed in E. coli*
**作者**: Zhang L, et al.
**摘要**: 本研究通过大肠杆菌表达系统成功制备重组人羧肽酶A1(CPA1)，利用X射线晶体学解析其2.1Å分辨率三维结构，揭示了活性位点关键氨基酸残基的构象特征，为胰腺外分泌功能障碍相关疾病的分子机制研究提供结构基础。
2. **文献名称**: *Optimization of CPA1 recombinant protein production in Pichia pastoris*
**作者**: Müller S, et al.
**摘要**: 通过毕赤酵母表达系统优化CPA1重组蛋白的分泌表达，采用pH调控和甲醇诱导策略使产量提升至120 mg/L。纯化蛋白经质谱验证正确分子量(45 kDa)，酶活检测显示其水解N端芳香族氨基酸的比活性达到天然酶的85%。
3. **文献名称**: *CPA1 autoantibodies in chronic pancreatitis: Diagnostic value of recombinant antigen-based ELISA*
**作者**: Li X, Wang Y.
**摘要**: 建立基于重组CPA1蛋白的ELISA检测方法，发现慢性胰腺炎患者血清中抗CPA1自身抗体阳性率达68%(n=120)，显著高于健康对照组(3%)。研究表明重组CPA1可作为特异性生物标志物用于胰腺炎早期诊断。
---
**检索建议**：如需真实文献，建议在PubMed/Web of Science中检索以下关键词：
- "CPA1 recombinant protein expression"
- "Carboxypeptidase A1 structural analysis"
- "CPA1 autoantibody diagnostic application"
可重点关注《Pancreas》《Protein Expression and Purification》等期刊近年发表的相关研究。
Carboxypeptidase A1 (CPA1) is a zinc-dependent metalloprotease primarily synthesized in the pancreas as an inactive zymogen (proCPA1). It plays a critical role in digestive physiology by cleaving C-terminal hydrophobic amino acids from dietary proteins, facilitating nutrient absorption. The mature enzyme is activated through proteolytic cleavage of its propeptide, a process mediated by trypsin in the duodenum. CPA1 is highly specific for substrates with aromatic or branched aliphatic side chains, contributing to its functional specialization in protein metabolism.
Recombinant CPA1 proteins are engineered using biotechnological platforms (e.g., E. coli, yeast, or mammalian cell systems) to produce purified enzyme variants for research and therapeutic applications. These recombinant forms enable detailed structural studies, including catalytic mechanism analysis and inhibitor development. Notably, CPA1 mutations have been linked to hereditary pancreatitis and pancreatic adenocarcinoma, making recombinant CPA1 valuable for investigating disease pathogenesis. Structural studies using recombinant protein have revealed key residues in substrate recognition and catalytic zinc coordination, providing insights for designing enzyme inhibitors.
Recent applications extend to biomarker discovery, as aberrant CPA1 expression correlates with pancreatic disorders. Pharmaceutical interest focuses on CPA1's role in activating prodrugs and its potential as a target for pancreatitis treatment. However, challenges persist in maintaining native conformation during recombinant production, as proper folding is essential for enzymatic activity. Ongoing research optimizes expression systems to improve yield and functionality, bridging the gap between biochemical characterization and clinical translation.
×
